Fourthly, as inhibitors of FGFs, FGFRs, SRC and αv integrins are in preclinical development or already available for clinical testing [37–40], these results provide a rationale for in vivo preclinical testing and focusing on their clinical assessment in invasive CRC. The gene discussed is SRC; the disease is colorectal carcinoma.